Alto Neuroscience, Inc. ANRO
Updated: 9 Aug 2026
No signal published yet
We already track Alto Neuroscience and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Alto Neuroscience, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Alto Neuroscience free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On July 13, 2026, Alto Neuroscience announced the pricing of a $100.0 million registered direct offering of common stock. Earlier in May 2026, the company reported its first-quarter 2026 financial results and highlighted the initiation of a Phase 2b clinical trial for ALTO-207 in treatment-resistant depression.
What Firelda Watch includes for Alto Neuroscience, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Alto Neuroscience, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Alto Neuroscience free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more